Management of Hyperthyroidism in Children and Adolescents
Abstract
Between 1961 and 1984, 262 patients with hyperthyroidism due to Graves' disease between the ages of 3 and 18 yr were treated in the author's clinic. This paper compares the results of different treatment methods. Initial treatment was surgery for 7 patients, radioiodine for 73, and an antithyroid drug for 182. Seven drug-treated patients subsequently had surgery. Of 14 surgically treated patients, 5 relapsed and received radioiodine, 5 became hypothyroid, 3 were lost to follow-up, and 1 remained euthyroid. Sixteen drug-treated patients were lost to follow-up; 7 are still taking drugs. Of the remaining 99 drug-treated patients not achieving remission, 92 received radioiodine, and 7 had surgery (1 later relapsed and received radioiodine). The principal reasons for abandoning drugs were toxicity, noncompliance, poor control, and failure to achieve sustained remissions. Of 61 drug-treated patients who achieved remission, 22 relapsed (21 were treated with radioiodine and 1 with drug). Remissions after antithyroid drug therapy persist in 39 patients, 2 of whom are now hypothyroid and 10 of whom have been in remission less than 2 yr. Of the 239 subjects whose treatment is complete, 191 (80%) ultimately had radioiodine. One radioiodine treatment eliminated hyperthyroidism in 163 patients, 2 treatments were effective in 17, and 3 treatments were effective in 1. The remaining 5 patients were lost to follow-up after radioiodine before the outcome of therapy could be determined. No increase in congenital abnormalities was found in 63 children of these patients, regardless of treatment. Radioiodine is a safe, simple, and economical therapy for patients with hyperthyroidism and is now considered the initial treatment of choice for such patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other studies of larger cohorts of pediatric patients with GD treated with ATDs for extended periods have not revealed similar remission rates.
“Although two decades ago it was suggested that 25% of children with GD go into remission with every 2 years of continued treatment (341), other studies of larger cohorts of pediatric patients with GD treated with ATDs for extended periods have not revealed similar remission rates (333,339,342).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [333]
30% of the children who went into remission eventually relapsed.
“Importantly, 30% of the children who went into remission eventually relapsed (333).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [333]
Of 120 pediatric patients treated with ATDs at one center, after 1 year of therapy 25% were in remission; after 2 years, 26%; after 4 years, 37%; and after 4-10 years, 15%.
“Of 120 pediatric patients treated with ATDs at one center, after 1 year of therapy with ATDs, 25% were in remission; after 2 years, 26%; after 4 years, 37%; and after 4-10 years, 15%.”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [333]
In children, when ATDs are used for 1-2 years, remission rates are generally 20%-30%, with remission defined as being euthyroid for 1 year after cessation of therapy.
“In children, when ATDs are used for 1-2 years, remission rates are generally 20%-30%, with remission defined as being euthyroid for 1 year after cessation of therapy (333,339,340).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [333]
MMI-related adverse events include allergic reactions, rashes, myalgias, and arthralgias, as well as hypothyroidism from overtreatment.
“MMI-related adverse events include allergic reactions, rashes, myalgias, and arthralgias (333,334), as well as hypothyroidism from overtreatment.”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [333]
Hypothyroidism typically develops by 2-3 months posttreatment.
“Hypothyroidism typically develops by 2-3 months posttreatment (333,349,350), at which time levothyroxine should be prescribed.”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [333]
The citation lists haven’t been fetched yet
References 26 · Cited by 161
- Authors
- HAMBURGER, J. I.
- Corresponding author
- HAMBURGER, JOEL I.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1985-05
- Volume
- 60
- Issue
- 5
- Pages
- 1019-1024
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2134617075
- Cited by
- 161
- References
- 26
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 2 · 2016: 4 · 2015: 6 · 2014: 9 · 2013: 3 · 2012: 8
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Pathology and Forensic Medicine › Ophthalmology and Eye Disorders
- Keywords
- hyperthyroidism, Graves' disease, children, adolescents, antithyroid drugs, radioiodine therapy, thyroidectomy, treatment outcomes, remission, hypothyroidism, drug toxicity, medication adherence, congenital malformations
- MeSH terms
- Adolescent, Child, Child, Preschool, Combined Modality Therapy, Female, Graves Disease, Humans, Hyperthyroidism, Iodine Radioisotopes, Male, Recurrence, Antithyroid Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review